{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:49:20Z","timestamp":1791434960627,"version":"4.3.3"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Retrospective cohort study using real\u2010world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025. Adults &gt;\u200955\u2009years with obesity, or overweight with \u2265\u20091 weight\u2010related comorbidity, without T2 diabetes who initiated tirzepatide for weight management were compared with propensity score\u2010matched individuals who did not receive any incretin\u2010based therapies. Changes in all\u2010cause healthcare costs (excluding tirzepatide; per\u2010person\u2010per\u2010month) between cohorts were assessed at 3\u20136, 6\u201312 and 12\u201318 months using a difference in differences (DiD) framework. Informative censoring and differential follow\u2010up were addressed with inverse\u2010probability\u2010of\u2010censoring\u2010weights and pairwise censoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Each cohort comprised 15843 individuals. Healthcare cost DiD estimates (95% CI) for the tirzepatide versus control cohorts were \u2212$145 (\u2212266, \u221225; 12.3% reduction;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022) during 6\u201312\u2009months and \u2212$319 (\u2212544, \u221294; 25.4% reduction;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015) during 12\u201318\u2009months; using pairwise censoring, estimates were \u2212$181 (\u2212319, \u221243;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021) and \u2212$607 (\u22121007, \u2212207;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023), respectively. Cost offsets with tirzepatide were driven by higher medical costs in controls during 12\u201318\u2009months (\u2212$211 [\u2212$407, \u2212$15];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.065) and fewer inpatient\/emergency department visits with tirzepatide versus controls; incidence rate ratio (95% CI) 0.69 (0.50, 0.94;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021) during 12\u201318\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Monthly cost offsets for persistent tirzepatide users versus untreated individuals grew over time, offsetting $319 (ranging from $94 to $544) tirzepatide costs by 12\u201318\u2009months. These results have implications for the $195 monthly net Medicare cost for the Bridge programme, suggesting tirzepatide may generate near\u2010term cost savings in an older population that stays on treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71250","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:09:56Z","timestamp":1787630996000},"page":"10418-10427","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in Cost of Care With Tirzepatide in Adults Aged Over 55\u2009Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3776-9596","authenticated-orcid":false,"given":"Navneet","family":"Upadhyay","sequence":"first","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bonakdar","sequence":"additional","affiliation":[{"name":"Cencora  Conshohocken Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshab","family":"Subedi","sequence":"additional","affiliation":[{"name":"Cencora  Conshohocken Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soutrik","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Aixial Group  Boulogne\u2010Billancourt France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Behrend","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9934-584X","authenticated-orcid":false,"given":"Emily R.","family":"Hankosky","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Centers for Disease Control and Prevention. Division of Nutrition Physical Activity and Obesity \u201cData Trends and Maps \u201daccessed June 17 2026 https:\/\/dnpao\u2010dtm.cdc.gov\/?page=national&topic=3&dataType=Adult%20Data&populationGroup=65%20or%20older&expandedIndicator=Q037&viz=table&tab=trend."},{"key":"e_1_2_10_3_1","unstructured":"Centers for Disease Control and Prevention \u201cConsequences of Obesity \u201daccessed June 17 2026 https:\/\/www.cdc.gov\/obesity\/php\/about\/consequences.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/obesity\/basics\/consequences.html."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247307"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14897"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1361915"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41514\u2010024\u201000148\u20102"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889\u2010022\u201013176\u2010y"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2333721415622004"},{"key":"e_1_2_10_10_1","unstructured":"\u201cReport of the Joint Economic Committee Congress of the United States on the 2023 Economic Report of the President \u201dJuly 27 2023 accessed June 19 2026 https:\/\/www.jec.senate.gov\/public\/_cache\/files\/c7df7ee3\u20102562\u201044f9\u2010bcc0\u2010fb038ff9967c\/the\u20102023\u2010joint\u2010economic\u2010report.pdf."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_10_13_1","volume-title":"ZEPBOUND (tirzepatide) Injection","year":"2026"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70991"},{"key":"e_1_2_10_15_1","unstructured":"A. S.Ward B.Tysinger P.Nguyen D. P.Goldman andD.Lakdawalla \u201cBenefits of Medicare Coverage for Weight Loss Drugs \u201dSchaeffer Center White Paper Series April 18 2023 accessed June 19 2026 https:\/\/schaeffer.usc.edu\/research\/benefits\u2010of\u2010medicare\u2010coverage\u2010for\u2010weight\u2010loss\u2010drugs\/."},{"key":"e_1_2_10_16_1","unstructured":"Centers for Medicare & Medicaid Services \u201cComing Soon: CMS to Provide $50 Monthly Access to GLP\u20101 Medications for Medicare Beneficiaries \u201d2026 News release May 6 2026 https:\/\/www.cms.gov\/newsroom\/press\u2010releases\/coming\u2010soon\u2010cms\u2010provide\u201050\u2010monthly\u2010access\u2010glp\u20101\u2010medications\u2010medicare\u2010beneficiaries."},{"key":"e_1_2_10_17_1","unstructured":"\u201cMedicare GLP\u20101 Bridge. Information for Pharmacies \u201daccessed June 17 2026 https:\/\/www.cms.gov\/medicare\/coverage\/prescription\u2010drug\u2010coverage\/medicare\u2010glp\u20101\u2010bridge\/information\u2010pharmacies."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.2894"},{"key":"e_1_2_10_19_1","unstructured":"\u201cKomodo Health \u201daccessed June 16 2026 https:\/\/www.komodohealth.com\/."},{"key":"e_1_2_10_20_1","unstructured":"Komodo Health Solutions \u201cImputing Allowed Amounts: Development and Validation of an Encounter\u2010Level Allowed Amount Imputation Model \u201d2023 accessed June 11 2026 https:\/\/knowledge.komodohealth.com\/hubfs\/2023\/Komodo_Imputing_Allowed_Amounts_White_Paper.pdf."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeconom.2020.12.001"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/clep.S49713"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"e_1_2_10_24_1","unstructured":"\u201cMedicare GLP\u20101 Bridge: Information for Part D Plans \u201daccessed June 17 2026 https:\/\/www.cms.gov\/medicare\/coverage\/prescription\u2010drug\u2010coverage\/medicare\u2010glp\u20101\u2010bridge\/information\u2010part\u2010d\u2010plans."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010023\u201001376\u20104"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15785"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49200"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2025.2610206"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","unstructured":"D.Wennberg H.Coetzer A.Marr et\u00a0al. \u201cThe Real\u2010World Costs of GLP\u20101 Receptor Agonist Treatment \u201dpreprint medRxiv https:\/\/doi.org\/10.1101\/2025.10.24.25338255.","DOI":"10.1101\/2025.10.24.25338255"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","unstructured":"C.Wing S.Cai D. W.Sacks andK. I.Simon \u201cDo GLP\u20101 Medications Pay for Themselves? National Bureau of Economic Research Working Paper 34678 \u201daccessed June 19 2026 http:\/\/www.nber.org\/papers\/w34678.","DOI":"10.3386\/w34678"},{"key":"e_1_2_10_31_1","unstructured":"G.Lopes S.Ikpe R.Moon andZ.Cao \u201cHealthcare Resource Utilization of Adult Patients With Obesity Before vs. After GLP\u20101 Treatment in the United States Elective Outpatient Setting \u201dPoster presented at ISPOR 2025 accessed June 19 2026 https:\/\/www.ispor.org\/docs\/default\u2010source\/cti\u2010meeting\u201021021\u2010documents\/1245ec6c\u2010d6d4\u20104656\u2010ac7e\u20101f5373f6b79c.pdf?sfvrsn=785c4910_0."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2026.32.3.281"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71250","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:59:43Z","timestamp":1791431983000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/dom.71250"],"URL":"https:\/\/doi.org\/10.1111\/dom.71250","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2026-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}